Focused On-demand Library for Translation initiation factor eIF-2B subunit gamma

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q9NR50

UPID:

EI2BG_HUMAN

Alternative names:

eIF-2B GDP-GTP exchange factor subunit gamma

Alternative UPACC:

Q9NR50; B2RBH8; D3DPZ2; Q5QP89; Q5QP90; Q8NDB5; Q8WV57; Q9H850

Background:

Translation initiation factor eIF-2B subunit gamma, also known as eIF-2B GDP-GTP exchange factor subunit gamma, plays a crucial role in protein synthesis by catalyzing the exchange of eukaryotic initiation factor 2-bound GDP for GTP. This process is vital for the initiation phase of protein synthesis, making it a key player in cellular function and health.

Therapeutic significance:

Leukoencephalopathy with vanishing white matter 3, a progressive brain disease, is linked to mutations affecting this protein. Understanding the role of Translation initiation factor eIF-2B subunit gamma could open doors to potential therapeutic strategies for this debilitating condition, highlighting its importance in medical research.